Eli Lilly attacks weight-loss drug knockoffs as competition intensifies
Eli Lilly unleashed a flurry of lawsuits against wellness centers, medical spas and others the pharmaceutical company accused of illegally…
Tag: Semaglutide
Study: Semaglutide Lowered Chronic Kidney Disease–Related Risks
Chronic kidney disease, most commonly caused by diabetes and high blood pressure, puts more than half a billion people globally at high…
Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024
Novo Nordisk announced the presentation of 34 abstracts highlighting the breadth of its portfolio at the upcoming 84th Scientific Sessions of…
Ozempic’s Hidden Challenges: A Personal Journey of Weight Loss and Self-Discovery
Author Johann Hari shares his experience with Ozempic, revealing both the benefits and unexpected psychological toll of the popular weight-loss…
Rethinking Exercise with GLP-1 Medications: Beyond Weight Loss
In the era of revolutionary type 2 diabetes medications like Ozempic, Mounjaro, and Trulicity, many patients are experiencing unprecedented weight…
GLP-1 Drugs Like Ozempic Set to Shake Up the Snack Food Industry
The snack food industry is bracing for a seismic shift as the popularity of GLP-1 medications, such as Ozempic and…
GLP-1 Drugs and Weight Loss Surgeries Demonstrate Comparable Reductions in Obesity-Related Cancers
A groundbreaking study has revealed that the use of GLP-1 receptor agonist medications, such as Ozempic and Wegovy, may be…
Study Reveals Lower GLP-1 Discontinuation Rates Among Endocrinologists’ Patients
Summary: A recent study published in the journal Diabetes Care has shed light on an intriguing trend in the prescription…
Beyond Weight Loss: Wegovy and Zepbound’s Added Health Benefits Attracting More Men, Doctors Say
The phenomenal success of weight-loss medications like Wegovy (semaglutide) and Zepbound (tirzepatide) has been primarily driven by their impressive ability…
Title: ENDO 2024: Ozempic Outperforms Mounjaro in Head-to-Head Weight Loss Trial
At the Endocrine Society’s annual meeting (ENDO 2024), highly anticipated results from a head-to-head trial comparing two popular weight-loss drugs,…
